<p>可以説，<strong>中集安瑞科</strong>（HKG:3899）目前的市盈率為 12.6 倍，相較於香港市場的中位數市盈率約為 12 倍，顯得相當 “中規中矩”。然而，如果市盈率沒有合理的基礎，投資者可能會忽視一個明顯的機會或潛在的挫折。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p>中集安瑞科最近的表現確實不錯，其盈利增長超過了大多數其他公司。一個可能性是，市盈率適中是因為投資者認為這種強勁的盈利表現可能即將減弱。如果你喜歡這家公司，你會希望這種情況不會發生，以便在它還未受到青睞時能夠買入一些股票。</p>
<p>查看我們對中集安瑞科的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497"/></p>
<p>SEHK:3899 市盈率與行業比較 2025 年 12 月 1 日</p>
<p>如果你想了解分析師對未來的預測，可以查看我們關於中集安瑞科的 <strong>免費</strong> 報告。</p>
<h2>中集安瑞科的增長趨勢如何？</h2>
<p>中集安瑞科的市盈率對於一家預計僅能實現適度增長的公司來説是典型的，重要的是，它的表現與市場保持一致。</p>
<p>回顧過去一年，該公司的淨利潤增長了 13%。最近三年期間，EPS 整體上升了 23%，在一定程度上得益於其短期表現。因此，可以公平地説，該公司的盈利增長在最近是相當可觀的。</p>
<p>展望未來，預計未來三年將實現每年 13% 的增長，這是由關注該公司的 11 位分析師的估計得出的。同時，市場的其他部分預計將每年增長 15%，這顯然更具吸引力。</p>
<p>考慮到這一點，令人好奇的是，中集安瑞科的市盈率與大多數其他公司相當。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票支付更高的價格。如果市盈率降至與增長預期更為一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
<h2>關鍵要點</h2>
<p>通常情況下，我們會警惕在做出投資決策時過度解讀市盈率，儘管它可以揭示其他市場參與者對公司的看法。</p>
<p>我們對中集安瑞科分析師預測的審查顯示，其較差的盈利前景並沒有像我們預期的那樣影響其市盈率。目前我們對市盈率感到不安，因為預測的未來盈利不太可能長期支持更積極的市場情緒。除非這些條件改善，否則很難接受這些價格是合理的。</p>
<p>值得注意的是，我們發現 <strong>中集安瑞科有 1 個警示信號</strong>，你需要考慮這一點。</p>
<p>如果這些 <strong>風險讓你重新考慮對中集安瑞科的看法</strong>，可以瀏覽我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>

中集安瑞科

<p>中集安瑞科控股有限公司的市盈率為 12.6 倍，在香港市場上被視為平均水平。儘管盈利增長可觀，分析師預測其增長速度將低於市場水平。如果增長預期未能實現，投資者可能會高估該股票，面臨未來失望的風險。該公司的市盈率並未反映其較差的盈利前景，這引發了對其當前估值的擔憂</p>

<p>It's not a stretch to say that <strong>CIMC Enric Holdings Limited's</strong> (HKG:3899) price-to-earnings (or &#34;P/E&#34;) ratio of 12.6x right now seems quite &#34;middle-of-the-road&#34; compared to the market in Hong Kong, where the median P/E ratio is around 12x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/E.</p>
<div class="lb-trans"><p>可以説，<strong>中集安瑞科</strong>（HKG:3899）目前的市盈率為 12.6 倍，相較於香港市場的中位數市盈率約為 12 倍，顯得相當 “中規中矩”。然而，如果市盈率沒有合理的基礎，投資者可能會忽視一個明顯的機會或潛在的挫折。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行探索。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p>CIMC Enric Holdings certainly has been doing a good job lately as it's been growing earnings more than most other companies. One possibility is that the P/E is moderate because investors think this strong earnings performance might be about to tail off. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's not quite in favour.</p>
<div class="lb-trans"><p>中集安瑞科最近的表現確實不錯，其盈利增長超過了大多數其他公司。一個可能性是，市盈率適中是因為投資者認為這種強勁的盈利表現可能即將減弱。如果你喜歡這家公司，你會希望這種情況不會發生，以便在它還未受到青睞時能夠買入一些股票。</p>
</div><p>Check out our latest analysis for CIMC Enric Holdings</p>
<div class="lb-trans"><p>查看我們對中集安瑞科的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497" alt="" original-src="https://images.simplywall.st/asset/chart/23554652-pe-multiple-vs-industry-1-dark-2/1764562581497"/></p>
<p>SEHK:3899 Price to Earnings Ratio vs Industry December 1st 2025</p>
<div class="lb-trans"><p>SEHK:3899 市盈率與行業比較 2025 年 12 月 1 日</p>
</div><p>If you'd like to see what analysts are forecasting going forward, you should check out our <strong>free</strong> report on CIMC Enric Holdings.</p>
<div class="lb-trans"><p>如果你想了解分析師對未來的預測，可以查看我們關於中集安瑞科的 <strong>免費</strong> 報告。</p>
</div><h2>How Is CIMC Enric Holdings' Growth Trending?</h2>
<div class="lb-trans"><h2>中集安瑞科的增長趨勢如何？</h2>
</div><p>CIMC Enric Holdings' P/E ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the market.</p>
<div class="lb-trans"><p>中集安瑞科的市盈率對於一家預計僅能實現適度增長的公司來説是典型的，重要的是，它的表現與市場保持一致。</p>
</div><p>Retrospectively, the last year delivered a decent 13% gain to the company's bottom line. The latest three year period has also seen a 23% overall rise in EPS, aided somewhat by its short-term performance. Therefore, it's fair to say the earnings growth recently has been respectable for the company.</p>
<div class="lb-trans"><p>回顧過去一年，該公司的淨利潤增長了 13%。最近三年期間，EPS 整體上升了 23%，在一定程度上得益於其短期表現。因此，可以公平地説，該公司的盈利增長在最近是相當可觀的。</p>
</div><p>Turning to the outlook, the next three years should generate growth of 13% per year as estimated by the eleven analysts watching the company. Meanwhile, the rest of the market is forecast to expand by 15% per year, which is noticeably more attractive.</p>
<div class="lb-trans"><p>展望未來，預計未來三年將實現每年 13% 的增長，這是由關注該公司的 11 位分析師的估計得出的。同時，市場的其他部分預計將每年增長 15%，這顯然更具吸引力。</p>
</div><p>In light of this, it's curious that CIMC Enric Holdings' P/E sits in line with the majority of other companies. It seems most investors are ignoring the fairly limited growth expectations and are willing to pay up for exposure to the stock. These shareholders may be setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.</p>
<div class="lb-trans"><p>考慮到這一點，令人好奇的是，中集安瑞科的市盈率與大多數其他公司相當。似乎大多數投資者忽視了相對有限的增長預期，並願意為接觸該股票支付更高的價格。如果市盈率降至與增長預期更為一致的水平，這些股東可能會為未來的失望埋下伏筆。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><p>Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.</p>
<div class="lb-trans"><p>通常情況下，我們會警惕在做出投資決策時過度解讀市盈率，儘管它可以揭示其他市場參與者對公司的看法。</p>
</div><p>Our examination of CIMC Enric Holdings' analyst forecasts revealed that its inferior earnings outlook isn't impacting its P/E as much as we would have predicted. Right now we are uncomfortable with the P/E as the predicted future earnings aren't likely to support a more positive sentiment for long. Unless these conditions improve, it's challenging to accept these prices as being reasonable.</p>
<div class="lb-trans"><p>我們對中集安瑞科分析師預測的審查顯示，其較差的盈利前景並沒有像我們預期的那樣影響其市盈率。目前我們對市盈率感到不安，因為預測的未來盈利不太可能長期支持更積極的市場情緒。除非這些條件改善，否則很難接受這些價格是合理的。</p>
</div><p>It is also worth noting that we have found <strong>1 warning sign for CIMC Enric Holdings</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>值得注意的是，我們發現 <strong>中集安瑞科有 1 個警示信號</strong>，你需要考慮這一點。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on CIMC Enric Holdings</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果這些 <strong>風險讓你重新考慮對中集安瑞科的看法</strong>，可以瀏覽我們的高質量股票互動列表，以瞭解還有哪些其他選擇。</p>
</div>

中集安瑞科控股有限公司（HKG:3899）的業務表現尚未與其股價相匹配